Generate a tailored SOP for Dr. Emma Aneheim. Improve your application with a focused, well-structured draft.
Emma Hilda Kristina Aneheim is affiliated with the University of Gothenburg, focusing on research in nuclear medicine and radiopharmaceutical chemistry. Her work primarily involves the development and application of radiolabeled compounds for use in targeted alpha therapy and preclinical evaluation of radionuclide therapies. Aneheim has co-authored several influential publications in the field, including studies on the optimization of labeling techniques for astatine-211 and its application in cancer therapy. Her research also explores the pharmacokinetics and biodistribution of radiolabeled antibodies and other biomolecules, contributing valuable insights to improve therapeutic efficacy in clinical settings. Additionally, she is involved in exploring the chemistry and infrastructure required for conducting clinical trials with astatine-211, emphasizing safety and effectiveness in cancer treatment. Through her scientific endeavors, Aneheim aims to bridge the gap between radiochemistry and clinical application, enhancing the potential of radionuclide therapies for cancer patients.
University of Gothenburg • Gothenburg, Sweden
Conducts research in nuclear medicine and radiopharmaceutical chemistry with a focus on astatine-211.
Administered by the Department of Political Science; focus on International Administration and Global Governance (IAGG).